EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Chem-CRISPR/dCas9FCPF: a platform for chemically induced epigenome editing

Mukaddes Altinbay, Jianhui Wang, Jie Chen, Daniel Schäfer, Maximilian Sprang iD, Biljana Blagojevic, Stefan Wölfl, Miguel A Andrade-Navarro iD, Ivan Dikic, Stefan Knapp iD, Xinlai Cheng iD

Nucleic Acids Research · 2024

DOI: 10.1093/nar/gkae798 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acids Research, 2024. Verfasst von Mukaddes Altinbay und 10 weiteren Autor:innen. Beteiligte Einrichtung: Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt am Main, Max-von-Laue-Straße 15, 60438 Frankfurt am Main, Germany. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing, Transcription Factors, Epigenesis, Genetic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, BMBF, Deutsche Krebshilfe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epigenetic aberration is one of the major driving factors in human cancer, often leading to acquired resistance to chemotherapies. Various small molecule epigenetic modulators have been reported. Nonetheless, outcomes from animal models and clinical trials have underscored the substantial setbacks attributed to pronounced on- and off-target toxicities. To address these challenges, CRISPR/dCas9 technology is emerging as a potent tool for precise modulation of epigenetic mechanism. However, this technology involves co-expressing exogenous epigenetic modulator proteins, which presents technical challenges in preparation and delivery with potential undesirable side effects. Recently, our research demonstrated that Cas9 tagged with the Phe-Cys-Pro-Phe (FCPF)-peptide motif can be specifically targeted by perfluorobiphenyl (PFB) derivatives. Here, we integrated the FCPF-tag into dCas9 and established a chemically inducible platform for epigenome editing, called Chem-CRISPR/dCas9FCPF. We designed a series of chemical inhibitor-PFB conjugates targeting various epigenetic modulator proteins. Focusing on JQ1, a panBET inhibitor, we demonstrate that c-MYC-sgRNA-guided JQ1-PFB specifically inhibits BRD4 in close proximity to the c-MYC promoter/enhancer, thereby effectively repressing the intricate transcription networks orchestrated by c-MYC as compared with JQ1 alone. In conclusion, our Chem-CRISPR/dCas9FCPF platform significantly increased target specificity of chemical epigenetic inhibitors, offering a viable alternative to conventional fusion protein systems for epigenome editing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsGene EditingTranscription FactorsEpigenesis, GeneticHumansAzepinesTriazolesHEK293 CellsProto-Oncogene Proteins c-mycCell Cycle ProteinsEpigenomeCRISPR-Associated Protein 9RNA, Guide, CRISPR-Cas SystemsBromodomain Containing Proteins

Substanzen

Transcription Factors(+)-JQ1 compoundAzepinesBRD4 protein, humanTriazolesProto-Oncogene Proteins c-mycCell Cycle ProteinsCRISPR-Associated Protein 9RNA, Guide, CRISPR-Cas SystemsMYC protein, human

Autor:innen und Institutionen

  • Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt am Main, Max-von-Laue-Straße 15, 60438 Frankfurt am Main, Germany.
  • Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Straße 9, 60438 Frankfurt am Main, Germany.
  • Frankfurt Cancer Institute, Paul-Ehrlich-Straße 42-44, 60596 Frankfurt am Main, Germany.
  • University Cancer Center (UCT) Frankfurt, Theodor-Stern-Kai7, 60590, Frankfurt am Main, Germany.
  • Faculty of Biology, Johannes Gutenberg University Mainz, Gresemundweg 2, 55128 Mainz, Germany.
  • Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Im Neuenheimer Feld 364, Heidelberg, Germany.

ORCID-Profile: Maximilian Sprang, Miguel A Andrade-Navarro, Stefan Knapp, Xinlai Cheng

Förderung

  • Deutsche Forschungsgemeinschaft
  • BMBF
  • Deutsche Krebshilfe
  • LOEWE Center Frankfurt Cancer Institute (FCI)
  • Hessen State Ministry of Higher Education, Research and the Arts
  • Open-Access-Publikationsfonds

Zitieren

APA

Altinbay, M., Wang, J., Chen, J., Schäfer, D., Sprang, M., Blagojevic, B., Wölfl, S., Andrade-Navarro, M. A., Dikic, I., Knapp, S., & Cheng, X. (2024). Chem-CRISPR/dCas9FCPF: a platform for chemically induced epigenome editing. Nucleic Acids Research. https://doi.org/10.1093/nar/gkae798

Vancouver

Altinbay M, Wang J, Chen J, Schäfer D, Sprang M, Blagojevic B, et al. Chem-CRISPR/dCas9FCPF: a platform for chemically induced epigenome editing. Nucleic Acids Research. 2024. doi:10.1093/nar/gkae798

BibTeX
@article{Altinbay2024,
  author = {Altinbay, Mukaddes and Wang, Jianhui and Chen, Jie and Schäfer, Daniel and Sprang, Maximilian and Blagojevic, Biljana and Wölfl, Stefan and Andrade-Navarro, Miguel A and Dikic, Ivan and Knapp, Stefan and Cheng, Xinlai},
  title = {Chem-CRISPR/dCas9FCPF: a platform for chemically induced epigenome editing},
  journal = {Nucleic Acids Research},
  year = {2024},
  doi = {10.1093/nar/gkae798}
}
Kostenlos starten →